Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.88 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -5.9 | |||||
3-Year EPS without NRI Growth Rate | -12.2 | |||||
3-Year FCF Growth Rate | -15.5 | |||||
3-Year Book Growth Rate | -22.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 59.72 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.33 | |||||
9-Day RSI | 54.09 | |||||
14-Day RSI | 50.91 | |||||
6-1 Month Momentum % | 6.86 | |||||
12-1 Month Momentum % | 35.4 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.55 | |||||
Quick Ratio | 8.55 | |||||
Cash Ratio | 7.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.3 | |||||
Shareholder Yield % | 0.24 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -98.21 | |||||
ROA % | -83.53 | |||||
ROIC % | -694.01 | |||||
3-Year ROIIC % | -322043.48 | |||||
ROC (Joel Greenblatt) % | -1573.15 | |||||
ROCE % | -97.76 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.83 | |||||
Price-to-Tangible-Book | 2.83 | |||||
EV-to-EBIT | -2.19 | |||||
EV-to-EBITDA | -2.21 | |||||
EV-to-Forward-Revenue | 17.6 | |||||
EV-to-FCF | -3.13 | |||||
Price-to-Net-Current-Asset-Value | 2.98 | |||||
Price-to-Net-Cash | 3.33 | |||||
Earnings Yield (Greenblatt) % | -45.66 | |||||
FCF Yield % | -21.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -3.328 | ||
Beta | 0.01 | ||
Volatility % | 63.63 | ||
14-Day RSI | 50.91 | ||
14-Day ATR (€) | 0.466883 | ||
20-Day SMA (€) | 9.6325 | ||
12-1 Month Momentum % | 35.4 | ||
52-Week Range (€) | 6.9 - 20.2 | ||
Shares Outstanding (Mil) | 43.22 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
KalVista Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(FRA:4XC1)'s stock price today?
When is next earnings date of KalVista Pharmaceuticals Inc(FRA:4XC1)?
Does KalVista Pharmaceuticals Inc(FRA:4XC1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |